(Q35563443)

8 August 2017

1 reference

title

Use of sibutramine to treat obesity (English)

1 reference

8 August 2017

0 references

1 reference

Donna H. Ryan

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14567156

22 March 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=14567156

22 March 2024

publication date

1 June 2003

1 reference

full work available at URL

8 August 2017

https://api.elsevier.com/content/article/PII:S0095454303000058?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/S0095-4543(03)00005-8

https://api.elsevier.com/content/article/PII:S0095454303000058?httpAccept=text/plain

22 March 2024

1 reference

https://api.crossref.org/works/10.1016/S0095-4543(03)00005-8

Primary Care: Clinics in Office Practice

22 March 2024

published in

1 reference

8 August 2017

volume

30

1 reference

8 August 2017

issue

2

1 reference

8 August 2017

page(s)

405-26, viii

1 reference

Body-Mass Index and Mortality in a Prospective Cohort of U.S. Adults

8 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900005-8

7 January 2021

Overweight and obesity in the United States: prevalence and trends, 1960-1994

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900005-8

7 January 2021

Prevalence and Trends in Obesity Among US Adults, 1999-2000

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900005-8

7 January 2021

Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900005-8

7 January 2021

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900005-8

1 reference

7 January 2021

Uses and misuses of the new pharmacotherapy of obesity

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900005-8

7 January 2021

Long-term weight control study. I (weeks 0 to 34). The enhancement of behavior modification, caloric restriction, and exercise by fenfluramine plus phentermine versus placebo

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900005-8

7 January 2021

Long-term weight control study. II (weeks 34 to 104). An open-label study of continuous fenfluramine plus phentermine versus targeted intermittent medication as adjuncts to behavior modification, caloric restriction, and exercise

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900005-8

7 January 2021

Long-term weight control study. III (weeks 104 to 156). An open-label study of dose adjustment of fenfluramine and phentermine

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900005-8

7 January 2021

Long-term weight control study. IV (weeks 156 to 190). The second double-blind phase

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900005-8

7 January 2021

Long-term weight control study. V (weeks 190 to 210). Follow-up of participants after cessation of medication

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900005-8

7 January 2021

Valvular heart disease associated with fenfluramine-phentermine

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900005-8

7 January 2021

Heart Valve Disorders and Appetite-Suppressant Drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900005-8

7 January 2021

Echocardiographic improvement over time after cessation of use of fenfluramine and phentermine

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900005-8

7 January 2021

Barriers to the Treatment of Obesity

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900005-8

7 January 2021

Sibutramine: a serotonin-norepinephrine reuptake-inhibitor for the treatment of obesity

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900005-8

7 January 2021

Thermogenic effects of sibutramine and its metabolites

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900005-8

7 January 2021

Modalities of the food intake-reducing effect of sibutramine in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900005-8

7 January 2021

Sibutramine reduces food intake in non-dieting women with obesity

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900005-8

7 January 2021

Thermogenic effects of sibutramine in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900005-8

7 January 2021

The effect of sibutramine on resting energy expenditure and adrenaline-induced thermogenesis in obese females

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900005-8

7 January 2021

Sibutramine produces dose-related weight loss

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900005-8

7 January 2021

Benefits of lifestyle modification in the pharmacologic treatment of obesity: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900005-8

7 January 2021

Long-term maintenance of weight loss after a very-low-calorie diet: a randomized blinded trial of the efficacy and tolerability of sibutramine

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900005-8

7 January 2021

Effect of sibutramine on weight maintenance after weight loss: a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900005-8

7 January 2021

Long-term weight loss with sibutramine: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900005-8

7 January 2021

Absence of cardiac valve dysfunction in obese patients treated with sibutramine.

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900005-8

7 January 2021

Sibutramine: a new weight loss agent without evidence of the abuse potential associated with amphetamines

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900005-8

7 January 2021

Effects of sibutramine alone and with alcohol on cognitive function in healthy volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900005-8

7 January 2021

A double-blind randomized placebo-controlled trial of sibutramine

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900005-8

7 January 2021

Sibutramine in overweight/obese hypertensive patients

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900005-8

7 January 2021

Obesity treatment with a progressive clinical tri-therapy combining sibutramine and a supervised diet--exercise intervention

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900005-8

7 January 2021

Efficacy and safety of sibutramine for weight loss in obese patients with hypertension well controlled by beta-adrenergic blocking agents: a placebo-controlled, double-blind, randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900005-8

7 January 2021

Evaluation of the safety and efficacy of sibutramine, orlistat and metformin in the treatment of obesity

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900005-8

7 January 2021

Treating obesity: a new target for prevention of coronary heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900005-8

7 January 2021

Effects of sibutramine on body weight and serum lipids: a double-blind, randomized, placebo-controlled study in 322 overweight and obese patients with dyslipidemia

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900005-8

7 January 2021

Six-month treatment of obesity with sibutramine 15 mg; a double-blind, placebo-controlled monocenter clinical trial in a Hispanic population

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900005-8

7 January 2021

A clinical trial of the use of sibutramine for the treatment of patients suffering essential obesity

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900005-8

7 January 2021

Efficacy and safety of sibutramine in obese white and African American patients with hypertension: a 1-year, double-blind, placebo-controlled, multicenter trial

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900005-8

7 January 2021

Randomized, double-blind, placebo-controlled, multicenter study of sibutramine in obese hypertensive patients

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900005-8

7 January 2021

Sibutramine is safe and effective for weight loss in obese patients whose hypertension is well controlled with angiotensin-converting enzyme inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900005-8

7 January 2021

Weight loss with sibutramine improves glycaemic control and other metabolic parameters in obese patients with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900005-8

7 January 2021

Sibutramine is effective for weight loss and diabetic control in obesity with type 2 diabetes: a randomised, double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900005-8

7 January 2021

Effects of sibutramine in obese female subjects with type 2 diabetes and poor blood glucose control

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900005-8

7 January 2021

Role of sibutramine in the treatment of obese Type 2 diabetic patients receiving sulphonylurea therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0095-4543%2803%2900005-8

7 January 2021

Sibutramine: a novel anti-obesity drug. A review of the pharmacological evidence to differentiate it from d-amphetamine and d-fenfluramine

series ordinal

21

1 reference

https://api.crossref.org/works/10.1016/S0095-4543(03)00005-8

Sibutramine and fat distribution: is there a role for pharmacotherapy in abdominal/visceral fat reduction?

22 March 2024

series ordinal

42

1 reference

https://api.crossref.org/works/10.1016/S0095-4543(03)00005-8

22 March 2024

Identifiers

1 reference

8 August 2017

1 reference